Loading...
Bright Green Corporation
BGXX•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$0.04
$0.00(0.00%)

The company's financials show resilient growth, with revenue advancing from -$5711.00 in Q4 2023 to $0.00 in Q3 2024. Gross profit remained healthy with margins at N/A in Q3 2024 compared to 2917% in Q4 2023. Operating income hit -$1.11M last quarter, sustaining a consistent N/A margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$1.11M. Net income rose to -$1.10M, while earnings per share reached -$0.006. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan